SEMA-VR is a prospective, randomized, 6-month long, open-label study of semaglutide.
Approximately 100 participants with type 2 diabetes and/or obesity will be randomized (1:1)
to receive semaglutide at escalating doses (up to 1.0 mg/week) or usual care without
semaglutide for 6 months.
The goal of this trial is to understand how semaglutide exerts cardio-protective effects in
people with type 2 diabetes and/or obesity. The main question it aims to answer is:
• Does semaglutide treatment preserve or increase the number of vessel-repairing cells
circulating in the blood?
Participants will:
- Be allocated to receive either semaglutide or usual care for 6 months
- Provide a blood sample at the baseline visit and another blood sample at the 6-month
visit
Researchers will compare participants receiving semaglutide to those receiving usual care for
any differences in the 6-month change in the number of vessel-repairing cells in the blood.
Phase:
Phase 4
Details
Lead Sponsor:
Canadian Medical and Surgical Knowledge Translation Research Group